US HB7391

Requires drug manufacturers to charge Federally-qualified health centers (FQHCs) no more than the 340B ceiling price at the point of purchase, rather than allowing higher upfront prices with later rebates or reimbursements

Amends Section 340B(a) of the Public Health Service Act (42 U.S.C. 256b(a)) to add new paragraph establishing upfront discounted pricing requirements

Prohibits arrangements where FQHCs pay above the 340B ceiling price at purchase time with later reconciliation through rebates, reimbursements, or other payments

Applies to all drug purchases made on or after enactment, including under existing manufacturer agreements with the Secretary

Introduced February 5, 2026 with bipartisan support (25 cosponsors) and referred to the House Committee on Energy and Commerce